Inventiva (NASDAQ:IVA) Hits New 12-Month High - What's Next?

Key Points

• Inventiva S.A. has reached a new 52-week high of $6.55, with recent trading volumes showing increased investor interest.
• Analysts exhibit a generally positive outlook, with six recommending a "buy" rating and one a "hold," while the average target price stands at $15.57.
• The company is focused on developing oral therapies, particularly for non-alcoholic steatohepatitis (NASH), with its lead product in Phase III clinical trials.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s stock price hit a new 52-week high on Friday . The company traded as high as $6.55 and last traded at $6.49, with a volume of 85139 shares. The stock had previously closed at $6.30.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Canaccord Genuity Group reissued a "buy" rating and set a $20.00 price objective on shares of Inventiva in a research report on Tuesday. Piper Sandler began coverage on Inventiva in a research report on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Inventiva in a research note on Saturday, September 27th. HC Wainwright initiated coverage on shares of Inventiva in a research note on Wednesday, September 3rd. They set a "buy" rating and a $20.00 target price for the company. Finally, Guggenheim raised their price target on shares of Inventiva from $9.00 to $13.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $15.57.

Inventiva Stock Performance

The stock has a fifty day simple moving average of $4.90 and a 200-day simple moving average of $3.85.

Hedge Funds Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Creative Planning acquired a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 10,000 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.